Archive · 5 Sep 2025
Glenmark Pharma Starts Global Trial of Lung Cancer Drug
Imagine a new medicine called Envafolimab to help people with lung cancer.
Glenmark Pharma is starting a big study to test it.
This study will include people from many countries like India, Russia, Brazil, and Mexico.
Envafolimab is given under the skin, which could make it easier for patients to get the medicine.
The study is to see if it helps people with a certain type of lung cancer (NSCLC).
The company hopes this medicine will become available worldwide, especially where it is harder to get healthcare.
The company's stock went up a little bit after the announcement.
Glenmark Pharma initiated a Phase 3 trial for Envafolimab.
The trial is for patients with resectable Stage III NSCLC.
Approval has been received from the Drugs Controller General of India.
Additional trial sites are planned in Brazil and Mexico.
Shares of Glenmark Pharma rose by 3.24%.
- Who
- Glenmark Pharmaceuticals Ltd
- What
- Initiated a Phase 3 clinical trial for Envafolimab
- When
- Initiated on Friday
- Where
- Multi-country (ex-China) including India, Russia, Brazil, and Mexico
- Why
- To evaluate the drug's efficacy, safety, and other factors in treating NSCLC.
- Company
- Glenmark Pharmaceuticals Ltd
- Drug
- Envafolimab (PD-L1 inhibitor)
- Trial Phase
- Phase 3
- Cancer Type
- Non-small cell lung cancer (NSCLC)
- Trial Setting
- Neoadjuvant/adjuvant
- Stock Rise
- 3.24%